Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
NCT07026110 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-06-18
Summary
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET/CT examinations and conventional 18F-FDG PET/CT in the diagnosis and differential diagnosis of solid lung nodules.
Conditions
- Lung Cancer
- Lung Diseases
- Lung Neoplasms
- Lung Cancer Metastatic
- Lung Inflammation
Interventions
- DRUG
-
[68Ga]Ga-NOTA-T4
Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
- DRUG
-
[68Ga]Ga-NOTA-RT4
Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
- DRUG
-
[18F]F-RESCA-T4
Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
- DRUG
-
[18F]F-RESCA-RT4
Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
- DRUG
-
[18F]F-RESCA-EPCD6
Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-EPCD6 injection.
- DRUG
-
[68Ga]Ga-NOTA-EPCD6
Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-EPCD6 injection.
Sponsors & Collaborators
-
RenJi Hospital
lead OTHER
Principal Investigators
-
Weijun Wei · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-23
- Primary Completion
- 2026-10-31
- Completion
- 2026-10-31
Countries
- China
Study Locations
More Related Trials
-
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
NCT04588064 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
NCT06203613 ·Status: RECRUITING ·Phase: NA
-
Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo
NCT02273271 ·Status: UNKNOWN ·Phase: NA
-
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117 ·Status: TERMINATED
-
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
NCT02938546 ·Status: UNKNOWN ·Phase: PHASE3
-
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
NCT02016872 ·Status: COMPLETED ·Phase: NA
-
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NCT04151940 ·Status: RECRUITING ·Phase: NA
-
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
NCT07301814 ·Status: RECRUITING
-
99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients
NCT01737112 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
NCT02511197 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC
NCT04996927 ·Status: UNKNOWN
-
Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules
NCT07087080 ·Status: RECRUITING ·Phase: NA
-
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160 ·Status: RECRUITING
-
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
NCT04813705 ·Status: RECRUITING ·Phase: PHASE2
-
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638 ·Status: RECRUITING ·Phase: PHASE2
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
NCT07102056 ·Status: NOT_YET_RECRUITING
-
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
NCT00004138 ·Status: COMPLETED ·Phase: NA
-
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
NCT04499365 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277 ·Status: NOT_YET_RECRUITING
-
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NCT06082492 ·Status: RECRUITING ·Phase: NA
-
Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy
NCT05828238 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
NCT06270394 ·Status: COMPLETED ·Phase: NA